Structured claim testing for lean life-science funds
We test the claims behind a seed or spinout deal, then deliver an inspectable artifact. Publishing that conclusion as authority is optional.
The short version
Biotica Bio provides scientific diligence that fits the consulting line partners already use — claim-tested, citation-backed memos for IC and syndicate close.
Hypothesis-driven diligence testing is the method. The product is the memo. Authority pages and discoverability are downstream effects, not the invoice line.
The problem
Investors need to know which claims must be true, what evidence supports them, what contradicts them, and what remains unresolved. That is a diligence question — and a consulting fee line item — not a marketing one.
Generic AI reports produce fluent narratives without making the underlying claims inspectable. Ad-hoc KOL notes are hard to share across a partnership.
We make claims inspectable: each one is tested, scored for support and contradiction, and tied to sources.
What Biotica Bio does
The thesis is decomposed into discrete, testable hypotheses across biology, translation, comparators, financing, and regulation.
Each claim is graded for supporting and contradicting evidence, with uncertainty stated rather than hidden.
The reviewed conclusion becomes a citation-backed, machine-readable page that is discoverable to humans and AI systems.
Why HDDT matters
Not a generic SEO agency
Not an unsupervised AI report
How diligence becomes authority
Investment question
What must be true for this fund to proceed?
Claim decomposition
The thesis is broken into discrete, falsifiable claims.
Evidence for and against
Independent literature, trials, patents, and comps — with human review.
Support / refute scoring
Each claim is graded; contradictions and gaps are named.
IC-ready memo
Investor-readable conclusion, priority questions, citation appendix.
Optional authority publish
When useful, the reviewed conclusion can become a durable public page.
Who it is for
Need: Translate strong science into claims investors can evaluate.
What they get: A structured account of what must be true, what the evidence shows, and where the story is still unproven.
Need: Independent structure for the claims behind an opportunity.
What they get: Support/refute scoring and comparator failure context that speeds an investment read without replacing judgment.
Need: Consistent diligence signal across a cohort.
What they get: Repeatable HDDT snapshots that make portfolio companies easier to compare and coach.
Need: Credible external framing for early translational assets.
What they get: Citation-backed authority pages that help licensing and financing conversations start from evidence.
Need: A fast, sourced read on an external technology or category.
What they get: Comparator maps and translational risk views that inform partnering and BD decisions.
Example output
| Hypothesis | Evidence support | Evidence against / uncertainty | Confidence | Investor implication |
|---|---|---|---|---|
| Prior clinical-stage EV failure modes are explicitly mapped (yield loss, batch variability, purification complexity, CDMO transfer risk). | Amass BioMedCore / TrialCore and public filings document a landmark clinical EV platform that reached Phase 1 then entered bankruptcy despite CDMO partnerships — establishing a concrete failure taxonomy for the category. | Company materials name the failure modes, but independent lot-level process data tying ExampleCo's process to each failure mode is still thin. | Moderate | The field failure map is real and diligence-useful; ExampleCo must still prove it is not repeating the same process risks. |
| Manufacturing is materially differentiated (simpler unit ops, defined cell line, analytics) versus those historical failures. | Company claims a defined upstream/downstream path (suspension culture, TFF/SEC-class purification) with identity and potency analytics intended for release. | Differentiation is largely asserted from process descriptions; independent multi-lot reproducibility and CDMO-transfer evidence are not yet public. | Moderate | Differentiation is the central value claim and remains conditionally supported — the gated experiment must measure it. |
| New biology, gene engineering, and delivery route do not introduce unbounded CMC complexity beyond manageable assays. | Published agonist and EV modality literature (Amass-retrieved) shows that assayable identity, ligand display, and potency readouts can bound complexity when they exist. | First-generation systemic agonists carried hepatotoxicity / weak-efficacy failure modes; engineered EV display adds new identity and density risks if assays are incomplete. | Moderate | Biology novelty is acceptable only if assay coverage is explicit; otherwise CMC risk expands with the science story. |
Prior clinical-stage EV failure modes are explicitly mapped (yield loss, batch variability, purification complexity, CDMO transfer risk).
ModerateManufacturing is materially differentiated (simpler unit ops, defined cell line, analytics) versus those historical failures.
ModerateNew biology, gene engineering, and delivery route do not introduce unbounded CMC complexity beyond manageable assays.
ModerateServices
Best for
Partners who need a narrow, fast read before spending IC time.
A focused test of 1–3 decision-critical claims — entry consulting scope in the low thousands.
Deliverables
Best for
IC prep, syndicate close, and spinout screens at lean LS funds.
A structured test of 5–8 core claims behind a company or thesis — priced like specialist scientific DD on the management-company OpEx line.
Deliverables
Best for
Deals that need deeper biology, comparator, CMC, and financeability coverage.
A fuller claim-tested narrative across the diligence dimensions that matter for the next financing.
Deliverables
Best for
Funds or founders who want the reviewed conclusion published as a durable asset.
Turn a reviewed diligence conclusion into a citation-backed web page — optional downstream of the diligence engagement, not the product you buy first.
Deliverables
Best for
Investors entering crowded or historically failed categories.
What happened to related companies, platforms, indications, financing paths, and clinical programs — and what that implies for this thesis.
Deliverables
Start with an HDDT Snapshot, or scope a full authority report.